Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 253

The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.

Neoadjuvant therapy with immune checkpoint blockade, antiangiogenesis, and chemotherapy for locally advanced gastric cancer

Open access
Li, Song, Yu, Wenbin, Xie, Fei, Luo, Haitao, Liu, Zhimin, Lv, Weiwei, Shi, Duanbo, Yu, Dexin, Gao, Peng, Chen, Cheng, Wei, Meng, Zhou, Wenhao, Wang, Jiaqian, Zhao, Zhikun, Dai, Xin, Xu, Qian, Zhang, Xue, Huang, Miao, Huang, Kai, Wang, Jian, Li, Jisheng, Sheng, Lei, Liu, Lian·2023·Nature Communications

Abstract

Despite neoadjuvant/conversion chemotherapy, the prognosis of cT4a/bN+ gastric cancer is poor. Immune checkpoint inhibitors (ICIs) and antiangiogenic agents have shown activity in late-stage gastric cancer, but their efficacy in the neoadjuvant/conversion setting is unclear. In this single-armed, phase II, exploratory trial (NCT03878472), we evaluate the efficacy of a combination of ICI (camrelizumab), antiangiogenesis (apatinib), and chemotherapy (S-1 ± oxaliplatin) for neoadjuvant/conversion treatment of cT4a/bN+ gastric cancer. The primary endpoints are pathological responses and their potential biomarkers. Secondary endpoints include safety, objective response, progression-free survival, and overall survival. Complete and major pathological response rates are 15.8% and 26.3%. Pathological responses correlate significantly with microsatellite instability status, PD-L1 expression, and tumor mutational burden. In addition, multi-omics examination reveals several putative biomarkers for pathological responses, including RREB1 and SSPO mutation, immune-related signatures, and a peripheral T cell expansion score. Multi-omics also demonstrates dynamic changes in dominant tumor subclones, immune microenvironments, and T cell receptor repertoires during neoadjuvant immunotherapy. The toxicity and post-surgery complications are limited. These data support further validation of ICI- and antiangiogenesis-based neoadjuvant/conversion therapy in large randomized trials and provide candidate biomarkers.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-022-35431-x

Cites

66 of 66 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 66 references

Cited by

See all 253

Metadata

Authors
Li, S., Yu, W., Xie, F., Luo, H., Liu, Z., Lv, W., Shi, D., Yu, D., Gao, P., Chen, C., Wei, M., Zhou, W., Wang, J., Zhao, Z., Dai, X., Xu, Q., Zhang, X., Huang, M., Huang, K., Wang, J., Li, J., Sheng, L., & Liu, L.
Venue
Nature Communications
Published
2023-01-03
Volume
14
Issue
1
Pages
8-8
ISSN
2041-1723 (ISSN-L)
OpenAlex
W4313528225
Cited by
253
References
66
FWCI
40.35
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Neoadjuvant therapy with immune checkpoint blockade, antiangiogenesis, and chemotherapy for locally advanced gastric cancer. https://app.cochat.ai/papers/10.1038/s41467-022-35431-x
The paper
Li, S., Yu, W., Xie, F., Luo, H., Liu, Z., Lv, W., Shi, D., Yu, D., Gao, P., Chen, C., Wei, M., Zhou, W., Wang, J., Zhao, Z., Dai, X., Xu, Q., Zhang, X., Huang, M., Huang, K., . . . Liu, L. (2023). Neoadjuvant therapy with immune checkpoint blockade, antiangiogenesis, and chemotherapy for locally advanced gastric cancer. Nature Communications. https://doi.org/10.1038/s41467-022-35431-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.